Opus Genetics, Inc

Quick facts

Phase 1 pipeline

• AAV8.hLCA5 · Ophthalmology
  Gene therapy for Leber congenital amaurosis 10 (LCA10)

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Opus Genetics, Inc portfolio CI brief
• Opus Genetics, Inc pipeline updates RSS